keyword
https://read.qxmd.com/read/38545845/inconsistency-in-steroid-use-as-antiemetics-in-clinical-trial-protocols-involving-immune-checkpoint-inhibitors-combined-with-chemotherapy
#1
JOURNAL ARTICLE
Soh Mee Park, Yu Jung Kim, Ju-Yeun Lee
OBJECTIVES: This study aims to investigate the use of steroids as antiemetics in clinical trials involving immune checkpoint inhibitors with chemotherapy. METHODS: Focusing on phase III trials registered before August 2023, it evaluated the consistency of steroid use guidelines. RESULTS: Out of 3452 trials screened, 44 were selected for in-depth review. The findings indicate a considerable variation: 13 trials did not specify the use of antiemetics, while 31 provided criteria for antiemetics, with 13 conforming to local standards, six to international guidelines, and five allowing either...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38518690/effect-of-peppermint-inhalation-versus-swedish-massage-on-chemotherapy-induced-nausea-and-vomiting-in-children-with-leukemia-multi-arm-randomised-trial-design
#2
JOURNAL ARTICLE
Eman Arafa Badr, Hawaa Mohamed Abdalla, Yousr Abd-Elsalam Gaafer, Maha Youssef Kamel
BACKGROUND: Chemotherapy is the foremost treatment for children with leukemia, while causing different serious side-effects. Chemotherapy-induced nausea and vomiting are the most common deliberating side effects and critical concerns of pediatric oncology nurses among those children. AIM: To investigate the effect of peppermint inhalation versus Swedish massage on chemotherapy-induced nausea and vomiting in children with leukemia. DESIGN: A multi-arm randomised trial design with three parallel groups...
March 21, 2024: Journal of Pediatric Nursing
https://read.qxmd.com/read/38515309/retrospective-analysis-of-real-world-prescribing-data-for-managing-cisplatin-based-chemotherapy-induced-nausea-and-vomiting-in-china
#3
JOURNAL ARTICLE
Xia Si, Hongyan Zhang, Qingming Ding, Gang Liu, Lin Huang, Xin Sun
BACKGROUND: The current utilization of neurokinin-1 receptor antagonists (NK1RAs) and the impact of updated guidelines on prescription patterns of antiemetic drugs among Chinese patients receiving highly emetogenic chemotherapy (HEC) remain undetermined. This study aims to analyze the present situation of Chinese cancer patients using antiemetic drugs and assess the appropriateness of antiemetic regimens. METHODS: Prescription data were collected between January 2015 and December 2020 from cancer patients receiving cisplatin-based chemotherapy at 76 hospitals in six major cities in China...
March 2024: Cancer Medicine
https://read.qxmd.com/read/38488197/the-effectiveness-of-p6-and-auricular-acupressure-as-a-complimentary-therapy-in-chemotherapy-induced-nausea-and-vomiting-among-patients-with-cancer-systematic-review
#4
REVIEW
Bushra Alhusamiah, Jumana Almomani, Ahmad Al Omari, Ala'a Abu Attallah, Afaf Yousef, Jafar Alasad Alshraideh, Ruqayya S Zeilani
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is one of the most prevalent and distressing side effects of chemotherapy among patients with cancer worldwide. Despite continuing advances in antiemetic medicines, nausea and vomiting associated with cancer chemotherapy remain a substantial therapeutic concern for many patients. However, P6 and Auricular acupressure (AA) have been recognized as potential therapy for managing chemotherapy-induced nausea and vomiting. AIM: This study aimed to evaluate the effectiveness of P6 and Auricular acupressure (AA) in reducing chemotherapy-induced nausea and vomiting among patients with cancer...
2024: Integrative Cancer Therapies
https://read.qxmd.com/read/38478773/cannabis-and-cannabinoids-in-adults-with-cancer-asco-guideline
#5
JOURNAL ARTICLE
Ilana M Braun, Kari Bohlke, Donald I Abrams, Holly Anderson, Lynda G Balneaves, Gil Bar-Sela, Daniel W Bowles, Peter R Chai, Anuja Damani, Arjun Gupta, Sigrun Hallmeyer, Ishwaria M Subbiah, Chris Twelves, Mark S Wallace, Eric J Roeland
PURPOSE: To guide clinicians, adults with cancer, caregivers, researchers, and oncology institutions on the medical use of cannabis and cannabinoids, including synthetic cannabinoids and herbal cannabis derivatives; single, purified cannabinoids; combinations of cannabis ingredients; and full-spectrum cannabis. METHODS: A systematic literature review identified systematic reviews, randomized controlled trials (RCTs), and cohort studies on the efficacy and safety of cannabis and cannabinoids when used by adults with cancer...
March 13, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38433125/characteristics-of-nausea-and-its-impact-on-health-related-quality-of-life-in-cisplatin-treated-patients-receiving-dexamethasone-sparing-prophylaxis-an-analysis-of-the-lung-nepa-study
#6
JOURNAL ARTICLE
Luigi Celio, Matti Aapro
PURPOSE: We investigated the intensity and duration of nausea as well as its impact on health-related quality of life among cisplatin-treated patients who participated in a study of dexamethasone (DEX)-sparing regimens based on NEPA (netupitant/palonosetron). METHODS: This retrospective analysis included chemo-naive patients from a trial evaluating non-inferiority of DEX on day 1 (DEX1 arm) combined with NEPA, compared with the same regimen with DEX administered on days 1-4 (DEX4; reference arm) following cisplatin (≥ 70 mg/m2 ) administration...
March 4, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38425339/case-report-a-rare-case-of-triple-negative-breast-cancer-with-development-of-acute-pancreatitis-due-to-dexamethasone-during-adjuvant-chemotherapy
#7
Hirofumi Ohmura, Taro Tobo, Yuki Ando, Takaaki Masuda, Koshi Mimori, Koichi Akashi, Eishi Baba
Here, we present the case of a 42-year-old female who developed acute pancreatitis due to dexamethasone during adjuvant chemotherapy for early triple negative breast cancer (TNBC). The patient received partial mastectomy and sentinel lymph node biopsy for early TNBC (cT1N0M0, cStage I) of the left breast. Dose-dense doxorubicin plus cyclophosphamide (ddAC) was administered as the adjuvant-chemotherapy; however, epigastralgia appeared on the fifth day of the first administration. A blood test showed a remarkable increase of serum pancreatic enzyme levels and computed tomography (CT) showed the swelling of pancreas and surrounding effusion, and she was diagnosed with moderate acute pancreatitis...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38425048/palonosetron-in-pediatric-patients-a-single-center-retrospective-evaluation-of-policy-and-clinical-practice-guideline-discordance
#8
JOURNAL ARTICLE
Meredith Ames, Priya Patel, L Lee Dupuis, Alicia Koo
INTRODUCTION: Clinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refractory CINV receiving HEC. Given the significant cost of palonosetron, we aimed to determine the proportion of chemotherapy blocks where palonosetron use was discordant with the institutional policy or source CPG...
February 29, 2024: Journal of Oncology Pharmacy Practice
https://read.qxmd.com/read/38417963/investigating-the-efficacy-and-safety-of-olanzapine-prophylaxis-for-opioid-induced-nausea-and-vomiting-jortc-pal20-a-study-protocol-for-an-open-label-single-arm-exploratory-study
#9
JOURNAL ARTICLE
Eriko Satomi, Tomomi Kobayashi, Ayaka Ishikawa, Sayaka Arakawa, Hiroto Ishiki, Koji Amano, Naomi Sakiyama, Keisuke Ariyoshi, Kota Kihara, Shunsuke Oyamada, Akio Mizushima
INTRODUCTION: In opioid therapy for cancer pain, opioid-induced nausea and vomiting (OINV) occur in 20%-40% of patients during initial opioid treatment or increasing opioid doses. OINV result in failure to achieve pain relief due to poor opioid adherence. Therefore, antiemetics are used to prevent OINV, but their efficacy and safety in this context have not yet been fully elucidated. Olanzapine is a promising antiemetic for the prophylaxis of chemotherapy-induced nausea and vomiting. METHODS AND ANALYSIS: This single-arm, single-centre exploratory study will evaluate the prophylactic antiemetic efficacy and safety of 5 mg olanzapine in patients with cancer pain who are withholding initial regular opioid therapy...
February 27, 2024: BMJ Open
https://read.qxmd.com/read/38417893/comparing-the-efficacy-of-fosnetupitant-an-nk-1-receptor-antagonist-in-cddp-based-regimens-with-that-of-fosaprepitant-and-aprepitant-a-retrospective-observational-study
#10
JOURNAL ARTICLE
Hiroshi Inano, Yoshihito Morimoto, Kanata Kitagawa, Akito Shibuya, Kozue Nakagomi, Tomohiro Ota, Yuri Anzo, Rika Miyauchi, Aiko Shono, Kazuhiro Watanabe, Katsuya Otori
Existing antiemetic therapy against emetic-risk agents across malignancies 24 h post-dose in the acute period in CDDP-based regimens yields a satisfactory complete response (CR) rate of ≥ 90%. However, the control rate after 24 h in the delayed period is unsatisfactory. This study compared the efficacy of fosnetupitant (F-NTP), a neurokinin 1 receptor antagonist, with that of fosaprepitant (F-APR) and aprepitant (APR) in the treatment of patients with cancer at high emetic risk due to chemotherapy. In this retrospective case-control study involving patients receiving cisplatin-containing regimens and neurokinin 1 receptor antagonists, patients were divided into three groups based on prophylactic antiemetic therapy: F-NTP, F-APR, and APR...
February 28, 2024: Biological & Pharmaceutical Bulletin
https://read.qxmd.com/read/38400861/adherence-to-antiemetic-guidelines-in-solid-cancer-patients-receiving-highly-emetogenic-chemotherapy-in-korea
#11
JOURNAL ARTICLE
Ryugyoung Lee, Minhee Ku, Nam Kyung Je
BACKGROUND: Highly emetogenic chemotherapy (HEC) is known to induce nausea and vomiting (CINV) in approximately 90% of cancer patients undergoing this regimen unless proper prophylactic antiemetics are administered. This study aimed to analyze the use of a three-drug prophylactic antiemetic regimen during the first cycle of chemotherapy and assess the compliance rate with the National Comprehensive Cancer Network (NCCN) guidelines. METHODS: This retrospective study utilized data from the National Inpatient Sample database from 2016 to 2020 provided by the Health Insurance Review and Assessment Service...
February 24, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38395266/targeting-autophagy-by-antipsychotic-phenothiazines-potential-drug-repurposing-for-cancer-therapy
#12
REVIEW
Rayssa M Lopes, Ana Carolina S Souza, Michał Otręba, Anna Rzepecka-Stojko, Ivarne L S Tersariol, Tiago Rodrigues
Cancer is recognized as the major cause of death worldwide and the most challenging public health issues. Tumor cells exhibit molecular adaptations and metabolic reprograming to sustain their high proliferative rate and autophagy plays a pivotal role to supply the high demand for metabolic substrates and for recycling cellular components, which has attracted the attention of the researchers. The modulation of the autophagic process sensitizes tumor cells to chemotherapy-induced cell death and reverts drug resistance...
February 21, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38395251/oral-mirtazapine-decreases-the-gastrointestinal-adverse-effects-in-cats-on-doxorubicin-chemotherapy
#13
JOURNAL ARTICLE
C H Lee, S L Wang
Anorexia, depression, and vomiting are the common adverse effects of chemotherapy in humans and animals. Mirtazapine is primarily used as an appetite stimulant and antiemetic in dogs and cats. Therefore, we evaluated the efficacy of mirtazapine in reducing the gastrointestinal adverse effects in cats receiving doxorubicin chemotherapy. This single-masked, placebo-controlled crossover study enrolled 11 cats with malignant mammary gland tumors. The cats were randomly assigned to receive either mirtazapine (1...
February 21, 2024: Veterinary Journal
https://read.qxmd.com/read/38371278/mechanism-underlying-conflicting-drug-drug-interaction-between-aprepitant-and-voriconazole-via-cytochrome-p450-3a4-mediated-metabolism
#14
JOURNAL ARTICLE
Masako Ishida, Takeshi Kumagai, Tatsuro Yamamoto, Hiroyuki Suzuki, Kuniaki Moriki, Masachika Fujiyoshi, Kiyoshi Nagata, Miki Shimada
BACKGROUND: Voriconazole is an antifungal drug for which therapeutic monitoring is recommended to prevent side effects. Temporary administration of the antiemetic drug fosaprepitant remarkably decreases the plasma concentration of voriconazole from the therapeutic range. The ratio of the major metabolite voriconazole N -oxide to voriconazole exceeded that at any other time for a patient who started chemotherapy during voriconazole therapy. We attributed this unpredictable result to cytochrome P450 3A4 induced by aprepitant that was converted from fosaprepitant in vivo...
February 2024: Yonago Acta Medica
https://read.qxmd.com/read/38341113/herbal-medicine-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-with-advanced-colorectal-cancer-a-prospective-randomized-controlled-trial
#15
RANDOMIZED CONTROLLED TRIAL
Zihong Wu, Xi Fu, Hailiang Jing, Wenbo Huang, Xueke Li, Chong Xiao, Zhuohong Li, Fengming You
ETHNOPHARMACOLOGICAL RELEVANCE: Chinese herbal medicine is increasingly used as complementary therapy to manage nausea and vomiting in different cultures. One such herbal recipe is the Hezhong granules, which contain classical antiemetic formulations, and are commonly used to prevent chemotherapy-induced nausea and vomiting (CINV). Modern pharmacological studies have shown that the key components of Hezhong granules, including Pinellia ternata (Thunb.), Evodia rutaecarpa (Juss.), and Zingiber officinale exhibit significant antiemetic and antitumor properties...
May 10, 2024: Journal of Ethnopharmacology
https://read.qxmd.com/read/38323173/comparison-of-oral-aprepitant-and-intravenous-fosaprepitant-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-pediatric-oncology-patients-a-randomized-phase-iii-trial
#16
JOURNAL ARTICLE
Li-Ting Yu, Zhuo Wang, Ya-Li Han, Fen Zhou, Lars M Wagner, Shun-Guo Zhang, Zhi-Ling Li, Yi-Jin Gao
BACKGROUND: Neurokinin-1 receptor antagonists have improved the management of chemotherapy-induced nausea and vomiting (CINV), but to date there has been no prospective comparison between oral aprepitant and intravenous fosaprepitant in pediatric oncology patients. METHODS: Our study was a double-parallel study, and the distribution ratio was 1:1. Children aged 2-12 years who were undergoing moderate or highly emetogenic chemotherapy (MEC or HEC) were randomly assigned to receive ondansetron and dexamethasone combined with either a single dose of intravenous fosaprepitant (arm A), or 3 days of oral aprepitant (arm B)...
January 29, 2024: Translational Pediatrics
https://read.qxmd.com/read/38279826/pediatric-oncology-provider-perspectives-and-patient-family-perceptions-of-chemotherapy-induced-nausea-and-vomiting-management-experiences-at-an-academic-medical-center
#17
JOURNAL ARTICLE
Hadley Bloomhardt, Melissa Rubin, Yanling Xue, Zhezhen Jin, Laura Masino, Drew Seidel, Nobuko Hijiya, Melissa Beauchemin
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is common in children undergoing cancer treatment, and significantly impacts quality of life. Clinical practice guidelines (CPGs) have been developed to guide CINV management, though many patients do not receive guideline-concordant care. Few studies have examined provider perspectives on CINV management or preferred improvement approaches, or pediatric patient perception of CINV control. METHODS: A cross-sectional study of pediatric oncology providers was conducted at a large freestanding children's hospital...
April 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38270801/intraperitoneal-and-hyperthermic-intraperitoneal-chemotherapy-for-the-treatment-of-ovarian-cancer
#18
REVIEW
Joyce Y Wang, Maya Gross, Renata R Urban, Soledad Jorge
In our clinical practice, we have shifted away from the use of adjuvant normothermic intraperitoneal (IP) chemotherapy, particularly following the publication of GOG 252. Our decision is rooted in the accumulating evidence indicating a lack of demonstrable superiority, alongside the recognized toxicities and logistical challenges associated with its administration. This strategic departure is also influenced by the rising utilization of maintenance therapies such as bevacizumab and PARP inhibitors, which present viable alternatives for improving patient outcomes...
January 4, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38267822/safety-and-tolerability-of-intravenous-aprepitant-and-fosaprepitant-in-children-with-cancer-a-retrospective-single-center-review
#19
JOURNAL ARTICLE
Srivarshini Kanukollu, Krisoula Spatz, Jessica A Lavery, Julia Glade Bender, Audrey Mauguen, Sherry Mathew
NK-1 receptor antagonists (NK1-RA) are key agents for chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy. Current pediatric practice guidelines recommend the use of intravenous fosaprepitant or oral aprepitant. However, there are reports of hypersensitivity reactions with fosaprepitant due to polysorbate 80. Intravenous aprepitant does not contain polysorbate 80, but its use in pediatric patients has not been described. In this retrospective, single-center study, 106 pediatric patients received either fosaprepitant or intravenous aprepitant as part of their antiemetic regimen...
April 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38237092/dexamethasone-free-antiemetic-prophylaxis-for-highly-emetogenic-chemotherapy-a-double-blind-phase-iii-randomized-controlled-trial-cinv-pod-study
#20
RANDOMIZED CONTROLLED TRIAL
Venkatraman Radhakrishnan, Kritthivasan Venkatakrishnan, Jayachandran Perumal Kalaiyarasi, Gangothri Selvarajan, Nizamudin Mahaboobasha, Paulson Vijaykumar Victor, Malarvizhi Anbazhagan, Deyva Manohari Sivanandam, Swaminathan Rajaraman
PURPOSE: The effectiveness of a dexamethasone (DEX)-free regimen for chemotherapy-induced nausea and vomiting (CINV) prophylaxis in patients receiving highly emetogenic chemotherapy (HEC) is not known. METHODS: This was a double-blind, phase III trial designed to show the noninferiority of a DEX-free regimen (olanzapine, palonosetron, and fosaprepitant [OPF]) compared with the DEX-containing regimen (olanzapine, palonosetron, and DEX [OPD]). Chemotherapy-naïve patients age 18-80 years receiving single-day HEC were randomly assigned 1:1 to receive either the OPD regimen or the OPF regimen...
January 2024: JCO global oncology
keyword
keyword
32975
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.